In this case report, the diagnosis of ADHD and the use of methylphenidate in two children with Muscular Dystrophy not otherwise specified will be discussed.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Studies from Western countries have indicated that psychiat- ric disorders, including Attention Deficit-Hyperactivity Disor- der (ADHD), are commonly seen in children and adolescents with Muscular Dystrophies.
📊
Key Findings & Data:Studies from Western countries have indicated that psychiat- ric disorders, including Attention Deficit-Hyperactivity Disor- der (ADHD), are commonly seen in children and adolescents with Muscular Dystrophies.
💡
Conclusion & Impact:In this case report, the diagnosis of ADHD and the use of methylphenidate in two children with Muscular Dystrophy not otherwise specified will be discussed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Studies from Western countries have indicated that psychiat- ric disorders, including Attention Deficit-Hyperactivity Disor- der (ADHD), are commonly seen in children and adolescents with Muscular Dystrophies. In this case report, the diagnosis of ADHD and the use of methylphenidate in two children with Muscular Dystrophy not otherwise specified will be discussed.
Özet
Batı toplumlarında yapılmış araştırmalar musküler distrofi tanılı çocuk ve ergenlerde, aralarında dikkat eksikliği hipe- raktivite bozukluğunun (DEHB) da bulunduğu, psikiyatrik bozuklukların sık olarak görüldüğüne işaret etmektedir. Bu olgu sunumunda, başka türlü adlandırılamayan musküler distrofisi olan iki çocuk hastada DEHB tanısı ve metilfenidat tedavisinin etkinlik ve güvenilirliği tartışıldı.
🔖
Cite This Article
EKİNCİ, Ö., ŞİLFELER, İ., ÇELİK, T., TOROS, F. (2022). Attention deficit hyperactivity disorder and the safety and efficacy of methylphenidate in muscular dystrophies: Two cases. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 25 - Sayı: 1, 69–72. https://ajindex.com/articles/571380
Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, ado- lescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26S-49S
Young HK, Barton BA, Waisbren S, Portales Dale L, Ryan MM, Webster RI, et al. Cognitive and psychological pro- file of males with Becker muscular dystrophy. J Child Neurol 2008;23(2):155-62
Sarnat HB. Muscular dystrophies. In: Berhman RE, Klieg- man RM, Jenson HB, editors. Nelson textbook of pediat- rics. 17th ed. Philedelphia: Saunders; 2004. p. 2060-9
Hendriksen JG, Vles JS. Neuropsychiatric disorders in males with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive-compulsive disorder. J Child Neurol 2008;23(5):477-81
Silfeler I, Arica V, Davran R, Tutanc M, Basarslan F. Fu- kuyama congenital muscular dystrophy. Pak J Med Sci 2012;28(3):519-21
Stein MT, Pachter LM, Schwartz L, Taras H. Disruptive classroom behavior in an amish school-age child with muscular dystrophy. J Dev Behav Pediatr 2004;25(5 Suppl):S102-6
Pane M, Lombardo ME, Alfieri P, DAmico A, Bianco F, Vasco G, et al. Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dys- trophy: phenotype-genotype correlation. J Pediatr 2012;161(4):705-9
Castellanos FX, Sonuga-Barke EJ, Milham MP, Tannock R. Characterizing cognition in ADHD: beyond executive dysfunction. Trends Cogn Sci 2006;10(3):117-23
Tomasi D, Volkow ND. Abnormal functional connectivity in children with attention-deficit/hyperactivity disorder. Biol Psychiatry 2012;71(5):443-50
Hendriksen JG, Vles JS. Are males with Duchenne mus- cular dystrophy at risk for reading disabilities? Pediatr Neurol 2006;34(4):296-300
Anderson JL, Head SI, Rae C, Morley JW. Brain function in Duchenne muscular dystrophy. Brain 2002;125(Pt 1):4- 13
Findling RL. Evolution of the treatment of attention-def- icit/hyperactivity disorder in children: a review. Clin Ther 2008;30(5):942-57
Rappley MD. Safety issues in the use of methylpheni- date. An American perspective. Drug Saf 1997;17(3):143- 8.